Key Developments: Anthera Pharmaceuticals Inc (ANTH.OQ)

ANTH.OQ on NASDAQ Stock Exchange Global Market

3.09USD
12:27pm EDT
Price Change (% chg)

$0.01 (+0.32%)
Prev Close
$3.08
Open
$3.12
Day's High
$3.14
Day's Low
$3.07
Volume
3,600
Avg. Vol
26,235
52-wk High
$4.60
52-wk Low
$2.59

Search Stocks

Latest Key Developments (Source: Significant Developments)

Anthera Pharmaceuticals announces acquisition of Sollpura
Monday, 14 Jul 2014 04:42pm EDT 

Anthera Pharmaceuticals Inc:Announces that it has acquired Sollpura (liprotamase), a novel investigational Pancreatic Enzyme Replacement Therapy (PERT) from Eli Lilly and Company.Sollpura is a soluble, stable and non-porcine enzyme product intended for the treatment of patients with low digestive enzyme levels, or Exocrine Pancreatic Insufficiency (EPI), due to cystic fibrosis, and potentially other diseases.  Full Article

Anthera Pharmaceuticals Inc Announces Auditor Change-Form 8-K
Wednesday, 4 Sep 2013 04:17pm EDT 

Anthera Pharmaceuticals Inc reported in its Form 8-K that the Audit Committee of the Board of Directors of Anthera Pharmaceuticals, Inc. (Company) has completed a competitive process to review the appointment of the Company’s independent registered public accounting firm for the year ending December 31, 2013. As a result of this process on August 29, 2013, the Audit Committee engaged BDO USA, LLP (BDO) as the Company’s independent registered public accounting firm, and dismissed Deloitte & Touche LLP (DT) from that role.  Full Article

Anthera Pharmaceuticals Inc Announces Initiation of BRIGHT-SC Phase2 Clinical Study in IgA Nephropathy with Blisibimod
Monday, 24 Jun 2013 08:30am EDT 

Anthera Pharmaceuticals Inc announced it has initiated the BRIGHT-SC Phase2 study of blisibimod, a novel inhibitor of B-Cell Activating Factor (BAFF) for the treatment of IgA nephropathy. IgA nephropathy is a chronic autoimmune renal disease characterized by proteinuria and progression to end stage renal disease.  Full Article

Anthera Pharmaceuticals Inc Announces CFO Change-Form 8-K
Thursday, 13 Jun 2013 06:01am EDT 

Anthera Pharmaceuticals Inc reported in its Form 8-K that Chief Business Officer and Chief Financial Officer (CFO), Christopher Lowe, will leave the Company effective June 30, 2013 to pursue other opportunities.  Full Article

Anthera Pharmaceuticals Inc Initiates CHABLIS-SC1 Phase 3 Clinical Study In Lupus With Blisibimod
Wednesday, 27 Mar 2013 04:15pm EDT 

Anthera Pharmaceuticals Inc announced it has initiated the CHABLIS-SC1 Phase 3 study of blisibimod, a inhibitor of B-Cell Activating Factor for the treatment of systemic lupus erythematosus. Lupus is a chronic autoimmune disease, which often leads to severe skin rash, fatigue, joint pain and organ complications. The Phase 3 CHABLIS-SC1 study is a multicenter, placebo-controlled, randomized, double-blind study designed to evaluate the efficacy, safety, tolerability and immunogenicity of blisibimod in patients with clinically active SLE who have not achieved optimal resolution of their disease with corticosteroid use. The study will enroll patients from Latin America, Asia Pacific and Commonwealth of Independent States who will be randomized to receive blisibimod or placebo for 52 weeks after which they will have the option to receive blisibimod therapy in an open-label, long-term, follow-up safety study. The study will enroll approximately 400 patients and the primary endpoint will be a Systemic Lupus Erythematosus Response Index-8. An SRI-8 responder is defined as a patient who has achieved a reduction in SELENA-SLEDAI equal to or greater than 8 points, and no new BILAG A or two B organ domain scores, and no increase in Physician's Global Assessment of greater than 0.3 on a three point scale. As part of the CHABLIS-SC1 clinical study an independent statistician will conduct interim analyses to validate key study assumptions.  Full Article

Faruqi & Faruqi, LLP Is Investigating Anthera Pharmaceuticals Inc On Behalf Of Shareholders
Wednesday, 13 Feb 2013 08:00am EST 

Faruqi & Faruqi, LLP, a national law firm concentrating on investor rights, consumer rights and the enforcement of federal antitrust laws, is investigating potential claims against the board of directors of Anthera Pharmaceuticals Incorporated concerning possible breaches of fiduciary duty and other violations of law related to the Company's compensation packages for executive officers. The investigation focuses on the approval and awarding of certain stock options to executives that may have violated the Company's compensation plans.  Full Article

Anthera Pharmaceuticals Inc Announces Pricing Of Public Offering Of Common Stock
Friday, 25 Jan 2013 08:57am EST 

Anthera Pharmaceuticals Inc announced the pricing of an underwritten public offering of 60,606,061 shares of common stock, offered at a price of $0.66 per share. The Company estimates that the gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Anthera, will be $40.0 million. The offering is expected to close on or about January 30, 2013. In addition, Anthera has granted the underwriters a 30-day option to purchase up to an additional 9,090,909 shares of common stock. The Company intends to use the net proceeds from the offering for general corporate purposes. Jefferies & Company, Inc. is acting as sole book-running manager in the offering and Leerink Swann LLC is acting as co-manager. Trout Capital LLC has acted as an advisor to the Company.  Full Article

Anthera Pharmaceuticals Inc Announces Proposed Public Offering Of Common Stock
Thursday, 24 Jan 2013 04:01pm EST 

Anthera Pharmaceuticals Inc announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. The Company intends to use the net proceeds from the offering for general corporate purposes. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Jefferies & Company, Inc. is acting as sole book-running manager in the offering and Leerink Swann LLC is acting as co-manager.  Full Article

The Law Firm of Levi & Korsinsky, LLP Launches Investigation Into Possible Breaches Of Fiduciary Duty By Board Of Directors Of Anthera Pharmaceuticals Inc. In Connection With Executive Compensation
Wednesday, 23 Jan 2013 02:55pm EST 

Levi & Korsinsky, LLP announced that it is investigating Anthera Pharmaceuticals, Inc., and its Board of Directors, in connection with the compensation provided to certain of its executive officers.  Full Article

Anthera Pharmaceuticals Inc Provides Clinical Progress Update
Wednesday, 24 Oct 2012 05:03pm EDT 

Anthera Pharmaceuticals Inc announced the new data from the PEARL-SC clinical study indicate strong trends towards increased time to first lupus flare (1.8-fold) and time to first severe lupus flare (1.6-fold) compared to placebo as defined by the SLE Flare Index. This index is used to document an increase in disease activity in one or more organ systems that results in new or the worsening of clinical signs and symptoms (and/or laboratory measurements). Additionally, there is usually a change in treatment, which includes increasing the dose of ongoing medications or the addition of new therapies. New analyses from the PEARL-SC clinical study also demonstrated an improvement in proteinuria over 24 weeks with 200 mg weekly blisibimod. These decreases in proteinuria resulted in the near normalization of the protein:creatinine ratio compared to baseline in patients who received blisibimod versus no improvement in the placebo group. The Company has completed discussions with the U.S. Food and Drug Administration (FDA) which will allow for the submission of Phase 3 protocols and the initiation of registration studies. FDA has confirmed the primary endpoint of SRI-8 evaluated at week 52 is acceptable for use in phase 3 clinical studies.  Full Article

Search Stocks